Published in Cancer Immunol Immunother on November 11, 2014
The role of photodynamic therapy in overcoming cancer drug resistance. Photochem Photobiol Sci (2015) 0.90
Boosting Tumor-Specific Immunity Using PDT. Cancers (Basel) (2016) 0.84
Photodynamic therapy: Promotion of efficacy by a sequential protocol. J Porphyr Phthalocyanines (2016) 0.80
Repurposing Drugs in Oncology (ReDO)-diclofenac as an anti-cancer agent. Ecancermedicalscience (2016) 0.76
Targeting Antitumor Immune Response for Enhancing the Efficacy of Photodynamic Therapy of Cancer: Recent Advances and Future Perspectives. Oxid Med Cell Longev (2016) 0.75
Oncologic Photodynamic Therapy: Basic Principles, Current Clinical Status and Future Directions. Cancers (Basel) (2017) 0.75
Photodynamic Synergistic Effect of Pheophorbide a and Doxorubicin in Combined Treatment against Tumoral Cells. Cancers (Basel) (2017) 0.75
Interaction and oxidative damage of DVDMS to BSA: a study on the mechanism of photodynamic therapy-induced cell death. Sci Rep (2017) 0.75
Selective events in the metastatic process defined by analysis of the sequential dissemination of subpopulations of a mouse mammary tumor. Cancer Res (1992) 9.02
Heterogeneity and cell-fate decisions in effector and memory CD8+ T cell differentiation during viral infection. Immunity (2007) 6.48
Photodynamic therapy of cancer: an update. CA Cancer J Clin (2011) 6.08
Cutting edge: rapid in vivo killing by memory CD8 T cells. J Immunol (2003) 4.25
Danger signals: SOS to the immune system. Curr Opin Immunol (2001) 3.91
The integration of T cell migration, differentiation and function. Nat Rev Immunol (2013) 2.42
The immunodominant major histocompatibility complex class I-restricted antigen of a murine colon tumor derives from an endogenous retroviral gene product. Proc Natl Acad Sci U S A (1996) 2.24
Enhanced systemic immune reactivity to a Basal cell carcinoma associated antigen following photodynamic therapy. Clin Cancer Res (2009) 1.80
Choice of oxygen-conserving treatment regimen determines the inflammatory response and outcome of photodynamic therapy of tumors. Cancer Res (2004) 1.80
Photodynamic therapy enhancement of antitumor immunity is regulated by neutrophils. Cancer Res (2007) 1.55
Role of cytokines in photodynamic therapy-induced local and systemic inflammation. Br J Cancer (2003) 1.52
Hypericin-based photodynamic therapy induces surface exposure of damage-associated molecular patterns like HSP70 and calreticulin. Cancer Immunol Immunother (2011) 1.51
CD40-independent pathways of T cell help for priming of CD8(+) cytotoxic T lymphocytes. J Exp Med (2000) 1.48
Mouse tumor rejection antigens P815A and P815B: two epitopes carried by a single peptide. Eur J Immunol (1992) 1.42
Altered expression of interleukin 6 and interleukin 10 as a result of photodynamic therapy in vivo. Cancer Res (1997) 1.42
Radical pleurectomy and intraoperative photodynamic therapy for malignant pleural mesothelioma. Ann Thorac Surg (2012) 1.39
The role of host lymphoid populations in the response of mouse EMT6 tumor to photodynamic therapy. Cancer Res (1996) 1.35
Immunology. Dangers in and out. Science (2009) 1.32
Evidence for an important role of neutrophils in the efficacy of photodynamic therapy in vivo. Cancer Res (1996) 1.28
Immunological and viral factors associated with the response of vulval intraepithelial neoplasia to photodynamic therapy. Cancer Res (2001) 1.26
Photodynamic therapy: illuminating the road from cell death towards anti-tumour immunity. Apoptosis (2010) 1.22
DAMPs and PDT-mediated photo-oxidative stress: exploring the unknown. Photochem Photobiol Sci (2011) 1.20
CD8+ T cell-mediated control of distant tumours following local photodynamic therapy is independent of CD4+ T cells and dependent on natural killer cells. Br J Cancer (2007) 1.14
Photodynamic therapy of tumors can lead to development of systemic antigen-specific immune response. PLoS One (2010) 1.12
Stimulation of anti-tumor immunity by photodynamic therapy. Expert Rev Clin Immunol (2011) 1.11
Cross-linking of signal transducer and activator of transcription 3--a molecular marker for the photodynamic reaction in cells and tumors. Clin Cancer Res (2007) 1.08
Photodynamic therapy enhancement of anti-tumor immunity. Photochem Photobiol Sci (2011) 1.00
Involvement of damage-associated molecular patterns in tumor response to photodynamic therapy: surface expression of calreticulin and high-mobility group box-1 release. Cancer Immunol Immunother (2011) 0.98
IL-17 promotes neutrophil entry into tumor-draining lymph nodes following induction of sterile inflammation. J Immunol (2013) 0.96
Photodynamic therapy of murine mastocytoma induces specific immune responses against the cancer/testis antigen P1A. Cancer Res (2013) 0.93
PDT-induced inflammatory and host responses. Photochem Photobiol Sci (2011) 0.90
Immunogenic cell death: can it be exploited in PhotoDynamic Therapy for cancer? Biomed Res Int (2012) 0.87
Interleukin-1α is the major alarmin of lung epithelial cells released during photodynamic therapy to induce inflammatory mediators in fibroblasts. Br J Cancer (2012) 0.86
Deletion of alloantigen-activated cells by aminolevulinic acid-based photodynamic therapy. Photochem Photobiol (1999) 0.84
Effects of photodynamic therapy with hypericin in mice bearing highly invasive solid tumors. Oncol Res (2000) 0.84
The effect of localized porphyrin photodynamic therapy on the induction of tumour metastasis. Br J Cancer (1987) 0.83
Synthesis, photophysical, electrochemical, tumor-imaging, and phototherapeutic properties of purpurinimide-N-substituted cyanine dyes joined with variable lengths of linkers. Bioconjug Chem (2011) 0.83
In vivo stability and photodynamic efficacy of fluorinated bacteriopurpurinimides derived from bacteriochlorophyll-a. J Med Chem (2006) 0.82
Peripheral tissue homing receptor control of naïve, effector, and memory CD8 T cell localization in lymphoid and non-lymphoid tissues. Front Immunol (2013) 0.81
Alteration of the metastatic potential of line 1 lung carcinoma cells: opposite effects of class I antigen induction by interferons versus DMSO or gene transfection. Cell Immunol (1990) 0.81
A retrospective review of pain control by a two-step irradiance schedule during topical ALA-photodynamic therapy of non-melanoma skin cancer. Lasers Surg Med (2013) 0.80
Photodynamic therapy of cancer: an update. CA Cancer J Clin (2011) 6.08
Enhanced systemic immune reactivity to a Basal cell carcinoma associated antigen following photodynamic therapy. Clin Cancer Res (2009) 1.80
Choice of oxygen-conserving treatment regimen determines the inflammatory response and outcome of photodynamic therapy of tumors. Cancer Res (2004) 1.80
Photodynamic therapy enhancement of antitumor immunity is regulated by neutrophils. Cancer Res (2007) 1.55
IL-6 trans-signaling licenses mouse and human tumor microvascular gateways for trafficking of cytotoxic T cells. J Clin Invest (2011) 1.46
Photodynamic therapy: a means to enhanced drug delivery to tumors. Cancer Res (2003) 1.37
Peroxiredoxin 1 stimulates secretion of proinflammatory cytokines by binding to TLR4. J Immunol (2009) 1.24
Activity of the vascular-disrupting agent 5,6-dimethylxanthenone-4-acetic acid against human head and neck carcinoma xenografts. Neoplasia (2006) 1.24
Peroxiredoxin 1 controls prostate cancer growth through Toll-like receptor 4-dependent regulation of tumor vasculature. Cancer Res (2011) 1.23
Photodynamic therapy and anti-tumor immunity. Lasers Surg Med (2006) 1.17
Light delivery over extended time periods enhances the effectiveness of photodynamic therapy. Clin Cancer Res (2008) 1.07
Conjugation of 2-(1'-hexyloxyethyl)-2-devinylpyropheophorbide-a (HPPH) to carbohydrates changes its subcellular distribution and enhances photodynamic activity in vivo. J Med Chem (2009) 1.07
Tumor vascular response to photodynamic therapy and the antivascular agent 5,6-dimethylxanthenone-4-acetic acid: implications for combination therapy. Clin Cancer Res (2005) 1.05
Treatment of diffuse basal cell carcinomas and basaloid follicular hamartomas in nevoid basal cell carcinoma syndrome by wide-area 5-aminolevulinic acid photodynamic therapy. Arch Dermatol (2005) 1.04
Toll-like receptor 5 agonist protects mice from dermatitis and oral mucositis caused by local radiation: implications for head-and-neck cancer radiotherapy. Int J Radiat Oncol Biol Phys (2011) 1.03
Assessment of the early effects of 5,6-dimethylxanthenone-4-acetic acid using macromolecular contrast media-enhanced magnetic resonance imaging: ectopic versus orthotopic tumors. Int J Radiat Oncol Biol Phys (2008) 1.01
Photodynamic therapy enhancement of anti-tumor immunity. Photochem Photobiol Sci (2011) 1.00
IL-17 promotes neutrophil entry into tumor-draining lymph nodes following induction of sterile inflammation. J Immunol (2013) 0.96
Differential contribution of TAP and tapasin to HLA class I antigen expression. Immunology (2008) 0.93
Peroxiredoxin 1 stimulates endothelial cell expression of VEGF via TLR4 dependent activation of HIF-1α. PLoS One (2012) 0.92
Photodynamic therapy with 3-(1'-hexyloxyethyl) pyropheophorbide a for cancer of the oral cavity. Clin Cancer Res (2013) 0.92
Purpurinimide carbohydrate conjugates: effect of the position of the carbohydrate moiety in photosensitizing efficacy. Mol Pharm (2007) 0.90
Bacteriopurpurinimides: highly stable and potent photosensitizers for photodynamic therapy. J Med Chem (2002) 0.88
A new finite element approach for near real-time simulation of light propagation in locally advanced head and neck tumors. Lasers Surg Med (2015) 0.87
A dose ranging study of photodynamic therapy with porfimer sodium (Photofrin) for treatment of basal cell carcinoma. Lasers Surg Med (2006) 0.87
What is the role of alternate splicing in antigen presentation by major histocompatibility complex class I molecules? Immunol Res (2010) 0.86
Treatment with the tumor necrosis factor-alpha-inducing drug 5,6-dimethylxanthenone-4-acetic acid enhances the antitumor activity of the photodynamic therapy of RIF-1 mouse tumors. Cancer Res (2003) 0.84
Identification of an alternate splice form of tapasin in human melanoma. Hum Immunol (2010) 0.83
The vascular disrupting agent 5,6-dimethylxanthenone-4-acetic acid improves the antitumor efficacy and shortens treatment time associated with Photochlor-sensitized photodynamic therapy in vivo. Photochem Photobiol (2008) 0.83
Enhanced sensitivity of colon tumour cells to natural killer cell cytotoxicity after mild thermal stress is regulated through HSF1-mediated expression of MICA. Int J Hyperthermia (2013) 0.80
The effect of photodynamic therapy on tumor cell expression of major histocompatibility complex (MHC) class I and MHC class I-related molecules. Lasers Surg Med (2012) 0.80
IL-6 potentiates tumor resistance to photodynamic therapy (PDT). Lasers Surg Med (2011) 0.79
In vitro photodynamic properties of chalcogenopyrylium analogues of the thiopyrylium antitumor agent AA1. J Med Chem (2002) 0.77
A prospective study of pain control by a 2-step irradiance schedule during topical photodynamic therapy of nonmelanoma skin cancer. Dermatol Surg (2014) 0.75
Granulocyte-macrophage colony-stimulating factor (GM-CSF) restores allostimulatory function to accessory cells in patients with AIDS. HIV Clin Trials (2002) 0.75
Water-soluble, core-modified porphyrins as novel, longer-wavelength-absorbing sensitizers for photodynamic therapy. II. Effects of core heteroatoms and meso-substituents on biological activity. J Med Chem (2002) 0.75
A beam-splitting device for use with fiber-coupled laser light sources for photodynamic therapy. Photochem Photobiol (2002) 0.75